doi: 10.1161/CIRCULATIONAHA.105.611350
(Circulation. 2006;113:2128-2151.)
© 2006 American Heart Association, Inc.
Controversies in Cardiovascular Medicine |
Is C-reactive protein an innocent bystander or proatherogenic culprit?
The Verdict Is Still Out
From the TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham & Women’s Hospital and Harvard Medical School, Boston, Mass (B.S, D.M.); Division of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Toronto, Canada (S.V.); Laboratory for Artherosclerosis and Metabolic Research, Department of Medical Pathology and Laboratory Medicine (S.D., I.J.), and Division of Endocrinology, Clinical Nutrition and Vascular Medicine, Department of Medicine (I.J.), University of California, Davis Medical Center, Sacramento.
Correspondence to David A. Morrow, MD, MPH, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (e-mail dmorrow@partners.org); Dr S. Verma, Division of Cardiac Surgery, St. Michael’s Hospital, 30 Bond St, Toronto, Canada (e-mail subodh.verma@sympatico.ca); or Dr I. Jialal, Laboratory for Artherosclerosis and Metabolic Research, University of California, Davis Medical Center, Sacramento, CA (e-mail ishwarlal.jialal@ucdmc.ucdavis.edu).
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
Introduction |
|---|
Presence at the scene of a crime is not itself necessarily compelling evidence of guilt.— Mark B. Pepys
The recognition of inflammation as a central contributor to atherothrombosis has engendered a sustained effort to characterize the specific participants and pathways and to identify noninvasive markers that enable detection of underlying inflammatory activation for the purpose of assessing cardiovascular risk. C-reactive protein (CRP), an acute-phase reactant, has been investigated in the pursuit of both of these objectives. Epidemiological studies have demonstrated an increased risk of cardiovascular events in patients with elevated levels of CRP.2–5 When considered together with experimental evidence placing CRP within arterial atheroma6–8 and clinical data revealing lowering of CRP with some preventive therapies, this strong base of epidemiological evidence has led to the hypothesis that CRP is both a marker of and a causal agent in the development of atherosclerosis.9,10 In other words, CRP may be both a "marker" and a "maker" of atherothrombosis.11 This hypothesis carries substantial clinical implications in that it forms the basis for both development of potential therapeutic agents that directly target CRP and consideration of CRP itself as a modifiable cardiovascular risk factor.
This unifying theory regarding CRP, while appealing, is not yet established by the available evidence.1,11 We will review the in vitro and in vivo data that support the assertion that CRP is itself pathogenic and the conflicting findings that render this conclusion premature.
|
CRP as a Marker of Clinical Risk |
|---|
To understand the basis for the intense investigation of CRP as a proatherogenic agent, it is
This article has been cited by other articles:
 |
|
 |
|
  C J Currie, C D Poole, and P Conway Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality Heart, April 1, 2008; 94(4): 457 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Singh, M. V. Suresh, D. C. Prayther, J. P. Moorman, A. E. Rusinol, and A. Agrawal C-Reactive Protein-Bound Enzymatically Modified Low-Density Lipoprotein Does Not Transform Macrophages into Foam Cells J. Immunol., March 15, 2008; 180(6): 4316 - 4322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Van Vre, H. Bult, V. Y. Hoymans, V. F.I. Van Tendeloo, C. J. Vrints, and J. M. Bosmans Human C-Reactive Protein Activates Monocyte-Derived Dendritic Cells and Induces Dendritic Cell-Mediated T-Cell Activation Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 511 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salio, S. Chimenti, N. De Angelis, F. Molla, V. Maina, M. Nebuloni, F. Pasqualini, R. Latini, C. Garlanda, and A. Mantovani Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction Circulation, February 26, 2008; 117(8): 1055 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent Am. J. Pathol., January 1, 2008; 172(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Nelson, N. Sattar, D. J. Freeman, J. D. Walker, and R. S. Lindsay Inflammation and Endothelial Activation Is Evident at Birth in Offspring of Mothers With Type 1 Diabetes Diabetes, November 1, 2007; 56(11): 2697 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ridker C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2129 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Arbustini Total Erythrocyte Membrane Cholesterol: An Innocent New Marker or an Active Player in Acute Coronary Syndromes? J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2090 - 2092. [Full Text] [PDF]
|
|
|
|
|
|
S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans Circulation, May 29, 2007; 115(21): 2715 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko and S. Verma C-Reactive Protein and Reendothelialization: NO Involvement Circ. Res., May 25, 2007; 100(10): 1405 - 1407. [Full Text] [PDF]
|
|
|
|
|
|
R. Schwartz, S. Osborne-Lawrence, L. Hahner, L. L. Gibson, A. K. Gormley, W. Vongpatanasin, W. Zhu, R. A. Word, D. Seetharam, S. Black, et al. C-Reactive Protein Downregulates Endothelial NO Synthase and Attenuates Reendothelialization In Vivo in Mice Circ. Res., May 25, 2007; 100(10): 1452 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig Serum Amyloid P Component and Cardiovascular Disease: Is There a Sensible Link? Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 698 - 700. [Full Text] [PDF]
|
|
|
|
 |
|
 NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar, H. M. Murray, A. McConnachie, G. J. Blauw, E. L.E.M. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, et al. C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation, February 27, 2007; 115(8): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rocker, D. E. Manolov, E. V. Kuzmenkina, K. Tron, H. Slatosch, J. Torzewski, and G. U. Nienhaus Affinity of C-Reactive Protein toward Fc{gamma}RI Is Strongly Enhanced by the {gamma}-Chain Am. J. Pathol., February 1, 2007; 170(2): 755 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blankenberg and S. Yusuf The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets? Circulation, October 10, 2006; 114(15): 1557 - 1560. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Devaraj, B. Davis, S. I. Simon, and I. Jialal CRP promotes monocyte-endothelial cell adhesion via Fc{gamma} receptors in human aortic endothelial cells under static and shear flow conditions Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1170 - H1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. D. Wiviott, M. A. Blazing, A. Shui, N. Rifai, R. M. Califf, and E. Braunwald Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial Circulation, July 25, 2006; 114(4): 281 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Davey Smith, N. Timpson, and D. A. Lawlor C-Reactive Protein and Cardiovascular Disease Risk: Still an Unknown Quantity? Ann Intern Med, July 4, 2006; 145(1): 70 - 72. [Full Text] [PDF]
|
|